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ARTICLE

A critical role for the host mediator
macrophage migration inhibitory factor
in the pathogenesis of malarial anemia
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3The

The pathogenesis of malarial anemia is multifactorial, and the mechanisms responsible for
its high mortality are poorly understood. Studies indicate that host mediators produced
during malaria infection may suppress erythroid progenitor development (Miller, K.L.,
J.C. Schooley, K.L. Smith, B. Kullgren, L.J. Mahlmann, and P.H. Silverman. 1989. Exp. Hematol.
17:379–385; Yap, G.S., and M.M. Stevenson. 1991. Ann. NY Acad. Sci. 628:279–281). We
describe an intrinsic role for macrophage migration inhibitory factor (MIF) in the development of the anemic complications and bone marrow suppression that are associated with
malaria infection. At concentrations found in the circulation of malaria-infected patients,
MIF suppressed erythropoietin-dependent erythroid colony formation. MIF synergized with
tumor necrosis factor and 𝛄 interferon, which are known antagonists of hematopoiesis,
even when these cytokines were present in subinhibitory concentrations. MIF inhibited
erythroid differentiation and hemoglobin production, and it antagonized the pattern of
mitogen-activated protein kinase phosphorylation that normally occurs during erythroid
progenitor differentiation. Infection of MIF knockout mice with Plasmodium chabaudi
resulted in less severe anemia, improved erythroid progenitor development, and increased
survival compared with wild-type controls. We also found that human mononuclear cells
carrying highly expressed MIF alleles produced more MIF when stimulated with the malarial
product hemozoin compared with cells carrying low expression MIF alleles. These data
suggest that polymorphisms at the MIF locus may influence the levels of MIF produced in
the innate response to malaria infection and the likelihood of anemic complications.
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Malaria is a systemic disease caused by infection
with parasitic protozoa of the genus Plasmodium
(1). Death results principally from the complications of infection: cerebral disease leading to
intractable coma and a severe and refractory anemia producing hypoxemia and cardiac decompensation. These complications of Plasmodium
infection have been estimated to account for
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at least 1–2 million deaths yearly, mostly in
African children under the age of five (1, 2).
The anemia of malaria infection is the result
of pathologic processes that act both to accelerate red cell destruction and to inhibit new red
cell production (3–5). Once infected by malarial parasites, red cells undergo lysis as a result
of the process of schizogony, wherein the cell
ruptures to release newly formed merozoites.
Immune-mediated lysis, phagocytosis, and sequestration also occur, and these contribute to
the increased clearance of nonparasitized as
well as parasitized cells (6, 7). Importantly, recent
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studies have led to the conclusion that enhanced red cell
clearance alone does not adequately explain the development
of malarial anemia, especially in those patients who develop
a severe, life-threatening disease (8, 9). Severe anemia can
occur in patients despite low parasitemia or as a result of
chronic subclinical infection, and it can persist for weeks after
the patient has been cured of infection and relocated to a
nonmalarial region (8, 10).
Detailed hematological studies in patients with severe
malarial anemia emphasize that bone marrow abnormalities
such as ineffective erythropoiesis, dyserythropoiesis, and
lower erythroblast proliferative rates contribute importantly
to the development of severe refractory anemia (9, 11–13).
Malaria-infected patients frequently show a suboptimal
reticulocyte count for the degree of anemia even in the face
of an appropriately high level of circulating erythropoietin,
which is the hormone critical for bone marrow erythropoiesis (14–16). These findings have been supported by
experimental studies in mice (17–20). Collectively, these
observations have served to focus attention on the pathogenesis of the bone marrow suppression that occurs during malaria infection and on the mechanisms that may contribute to
the resistance of erythroid progenitor cells to the action of
circulating erythropoietin (21).
Several investigators have proposed that a dysregulation
in host immunologic pathways is responsible for the suppression of erythropoiesis during malaria infection (22, 23).
Potential mechanisms include an excessive or a sustained innate
immune response (24) and a polarization of the adaptive
T cell response toward the production of mediators that
might suppress normal pathways of erythropoietic development (15, 25, 26). Experimental studies in mice support the
concept that malaria infection induces in the host the production of a potent circulating inhibitor of erythropoiesis
(19, 27, 28). This erythropoiesis inhibitor has been partially
characterized with respect to its biologic and biophysical
properties (27, 28). Cytokines such as TNFα, IL-1β, and
IFNγ that are produced systemically during malaria infection
have been considered as candidates for this inhibitory mediator, but experimental studies have ruled out an important
role for these cytokines in mediating erythroid suppression
(20). A recent and unexpected set of observations from malaria vaccine trials also has focused attention on the immunopathogenesis of malarial anemia (29). Vaccination and challenge
infection in Aotus monkeys produces severe anemia in a
subset of animals that achieves initial immunity. The precise
explanation for this vaccine-related anemia is unknown, but
hematologic investigations in these hosts have supported
a role for impaired erythropoiesis.
In this study, we have investigated whether the immunoregulatory cytokine macrophage migration inhibitory factor
(MIF) plays a role in the pathogenesis of malaria anemia. MIF
has been proposed to contribute to the pathogenesis of malaria
based on its abundant expression in an experimental mouse
model and on the biophysical features it shares with the previously characterized circulating inhibitor of erythropoiesis (30).
1186

Figure 1. Dose-dependent impact of MIF, TNF𝛂, and IFN𝛄 on colony
formation in mouse bone marrow progenitor cultures in vitro. Bone
marrow cells were harvested and plated in a methylcellulose-based
medium, and colony numbers were scored after the addition of mouse
cytokines (see Materials and methods). Individual assays were performed
in duplicate, and the data shown is a compilation of three to six independently performed experiments. Percent inhibition of colony formation is
calculated with reference to a cytokine-minus control. All values shown
are the mean ± SD (error bars) and are significant when compared with
wells with no cytokine addition (P < 0.05). CFU-E, CFU erythroid; BFU-E,
burst-forming unit erythroid.

Using a combination of in vitro studies of erythroid progenitors and in vivo studies in MIF-KO mice, we show that MIF
has an intrinsic role in the pathogenesis of the bone marrow
suppression that occurs during malaria infection.
RESULTS
Effect of MIF and proinflammatory cytokines
on erythropoiesis in vitro
Several inflammatory cytokines interfere with hematopoiesis, and there is evidence that MIF may inhibit progenitor
development in vitro (30). We examined the effect of MIF
on mouse erythroid precursor development using defined
erythropoietin-dependent colony assays, including both the
early burst-forming unit erythroid (BFU-E) and the late
CFU erythroid (CFU-E). We also studied the two inflammatory cytokines TNFα and IFNγ, which are produced as a
consequence of macrophage and T cell activation and are
implicated in severe malarial anemia (4). The appearance of
BFU-E and CFU-E were quantified after culture with these
MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
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Figure 2. MIF inhibits cytodifferentiation and hemoglobin synthesis of MEL cells. (A) Photomicrographic images of benzidine-stained
cells from three experiments (I, II, and III) cultured with or without differentiation medium for 96 h together with 200 ng/ml recombinant mouse

MIF or MIF plus 100 μg/ml anti-MIF mAb. (B) Intracellular hemoglobin
quantification of lysed MEL cells (4 × 105 cells per experiment) as described in Materials and methods. Each value represents the mean ± SD
(error bars) of five different experiments. *, P < 0.01 versus control.

cytokines, which were applied either alone or in combination. As shown in Fig. 1, the addition of 10–100 ng/ml MIF,
1–20 ng/ml TNFα, or 10–100 U/ml IFNγ dose dependently inhibited BFU-E and CFU-E colony formation. The
early stage BFU-E showed greater inhibition than the late
stage CFU-E colonies at each of the doses tested. Notably,
the addition of subinhibitory concentrations of MIF together
with TNFα and IFNγ resulted in a profound and synergistic
inhibitory action. Synergism in effector function is not unusual for cytokine action, and the ability of MIF to lower the
response threshold to other cytokines has been noted in prior
studies of other cell systems (31–33).

mAb. Quantification of cellular hemoglobin by a sensitive
chemical analysis also showed that lower amounts of MIF (20
and 100 ng/ml) reduced hemoglobin content by 12 and 20%,
respectively (Fig. 2 B).
We then tested the effect of MIF stimulation on the human K562 progenitor cell line by coculturing these cells
under differentiation conditions in the presence of MIF. As
shown in Fig. 3 A, MIF inhibited the terminal erythropoietic differentiation of these cells as measured by a sensitive
diaminofluorene (DAF) stain (38). The impact of MIF on
hemoglobin production in these cells also was verified by
biochemical quantification of intracellular hemoglobin content (Fig. 3 B). Neither MIF nor anti-MIF was found to exert
cytotoxic effects on erythroid progenitors as assessed by trypan blue exclusion (unpublished data).

MIF suppresses erythroid differentiation in progenitor
cell lines
We next sought to identify the potential pathways responsible for the MIF-mediated impairment of erythroid differentiation. Erythroid progenitors such as the Friend mouse
erythroleukemia (MEL; reference 34) or the human K562
(35) cell line undergo cytodifferentiation in vitro, leading to
the initiation of hemoglobin synthesis and to a more mature
erythroid phenotype. We examined these model cell systems
because they replicate certain features of erythroid differentiation and they are more amenable to biochemical analysis
than methylcellulose cultures of primary progenitor cells.
Cultured MEL cells were induced to undergo cytodifferentiation in the presence of recombinant MIF and were analyzed for intracellular hemoglobin content by benzidine
staining. At a test concentration of 200 ng/ml, which is an
amount of MIF that may circulate during severe systemic infection (36, 37), MIF decreased the cytodifferentiation response of MEL cells (Fig. 2 A). The specificity of this effect
was verified by the application of a neutralizing anti-MIF
JEM VOL. 203, May 15, 2006

MIF modulates MAP kinase activation
Having uncovered a prominent inhibitory effect of MIF on
the differentiation of K562 cells, MEL cells, and primary
erythroid progenitors, we next examined the signaling
mechanisms influenced by MIF stimulation. Erythropoiesis
requires the coordinate activation of several growth factor–
dependent signal transduction pathways (39, 40), and some
of these pathways may be faithfully represented in model
progenitor cell systems. For example, both primary erythroid
and K562 progenitor cells exhibit differentiation-dependent
modulation in the different subfamilies of the mitogenactivated protein (MAP) kinases (extracellular signal-related
kinase [ERK]–1/2, c-Jun NH2-terminal kinase [JNK]–1/2,
and p38; reference 35).
MIF promotes proinflammatory functions in monocytes/
macrophages and fibroblasts by activating the ERK-1/2
family of MAP kinases (41). A distinguishing feature of MIF
1187

associated MAP kinase responses. In the case of the ERK-1/2
subfamily, phosphorylation was high at 16 h after MIF stimulation and, in a pattern that is consistent with other primary
cell types (41), was sustained for a period of at least 96 h
(16 h, P < 0.01; 96 h, P < 0.05; Fig. 4 A). MIF addition also
appeared to up-regulate JNK-1/2 phosphorylation when
compared with differentiation medium alone; however, this
effect was not as pronounced as for ERK-1/2 and did not
reach statistical significance (96 h, P < 0.06; Fig. 4 B). Nevertheless, the differentiation-associated changes in p38 MAP
kinase phosphorylation were reduced by MIF (16 h, P <
0.01; 96 h, P < 0.04; Fig. 4 C). The phosphorylation patterns induced by MIF were normalized by anti-MIF mAb
(96 h: ERK-1/2, P < 0.04; p38, P < 0.04; for anti-MIF
mAb treatment vs. nontreatment), and the time course for
these effects was consistent with the increase in hemoglobin
synthesis observed after anti-MIF treatment (Figs. 3 and 4).
These data support the role of MIF in inhibiting erythroid
differentiation by modulating MAP kinase activation.

Figure 3. MIF inhibits cytodifferentiation and hemoglobin production in human (K562) erythroid progenitors. (A) Terminal erythropoietic differentiation was assayed as described in Materials and methods
with diaminofluorene (DAF) after culture in differentiation medium together with 200 ng/ml MIF for 96 h as described in Materials and methods. The neutralizing anti-MIF mAb was added at 100 μg/ml. DAF-positive
cells were enumerated and expressed as fold change over total input cells.
(B) Cellular hemoglobin content of cultured K562 progenitor cells. An
isotypic control (IgG1) added in the same concentration had no impact on
MIF’s inhibitory action, nor did anti-MIF influence differentiation in the
absence of MIF (not depicted). Each value represents the mean ± SD
(error bars) of at least three different experiments. *, P < 0.01 versus
corresponding controls.

action is that it induces a sustained rather than a transient
pattern of ERK-1/2 activation (41), which is noteworthy
because the kinetics of ERK-1/2 activation influence the
differentiation pathway of different progenitor cell types (42).
We cultured K562 progenitors in differentiation medium together with MIF or MIF plus a neutralizing anti-MIF mAb
and analyzed the cell lysates using phospho-specific antibodies
directed against different MAP kinases. In agreement with
published results (35), we observed that the erythroid differentiation of K562 progenitors is associated with a time-dependent
inhibition of ERK-1/2 and JNK-1/2 phosphorylation (beginning at 16 and 96 h, respectively) and a complementary activation of the p38 phosphorylation (beginning at 16 h; Fig. 4,
A–C). MIF addition markedly affected these differentiation1188

MIF mediates anemia in experimental malaria infection
After intraperitoneal injection with a modest inoculum of
Plasmodium chabaudi–parasitized red blood cells (106 per
mouse), the BALB/c mouse strain develops an acute parasitemia that peaks on approximately day 8 of infection (43).
More than 50% of mice will succumb to infection by 3 wk,
and anemia notably contributes to death because the administration of a blood transfusion late in infection can rescue up
to 90% of the infected mice (44).
To determine the role of MIF in the anemic complications of acute malaria infection in vivo, we backcrossed a
recently developed MIF-KO strain (45) into the BALB/c
genetic background for experimental infection with P. chabaudi.
Before study, we first assessed the hematopoietic competence
of the MIF-KO strain by bone marrow histochemistry and
enumeration of the different hematopoietic lineages. There
were no differences between wild-type controls and MIFKO mice with respect to the number of mature peripheral
blood cells or in the numbers of CFU-E and BFU-E in bone
marrow (unpublished data). Infection of wild-type or MIFKO mice with P. chabaudi AS resulted in a prominent parasitemia that peaked on postinfection day 8 at 47 ± 15%.
Peripheral blood was sampled every 2 d, and there was no
appreciable difference in the mean level of parasitemia in the
wild-type versus the MIF-deficient mice over the 4-wk course
of the study (unpublished data). Despite the similar levels of
parasitemia, however, the severity of anemia that developed
in the two different experimental groups was quite different,
especially as the infection progressed (Fig. 5 A). Hemoglobin
levels progressively declined in the wild-type mice, with the
lowest levels recorded on postinfection day 15, after which
time >90% of the animals in this group perished. In comparison, the MIF-KO mice experienced a less severe anemia
than the wild-type mice, and this difference remained statistically significant after the first week. Notably, the onset of
death for mice in the MIF-KO group was delayed by 2 d
MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
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Figure 4. Western blot analysis of the phosphorylation of MAP
kinase proteins ERK-1/2, JNK-1/2, and p38 in response to cytodifferentiation and MIF treatment of K562 erythroid progenitors. For
each experiment, 30 μg of cell lysates were subjected to SDS-gel electrophoresis and electroblotting followed by incubation with specific antiphospho–ERK-1/2 or total ERK (A), antiphospho–JNK-1/2 or total JNK
antibodies (B), and antiphospho-p38 or total p38 antibodies (C). 100 μg/ml
of neutralizing anti-MIF mAb showed no influence on MAP kinase activa-

tion in the absence of exogenously added MIF (not depicted). One representative blot is shown from at least three independently performed cell
culture experiments for each kinase analysis. (D) Densitometric values
were calculated as the ratio of phosphorylated to total MAP kinase as
described in Materials and methods (n = 3 blots from independent experiments; mean ± SEM). Significance was calculated for each treatment
condition (MIF or MIF + anti-MIF) versus nontreatment for each time
point (4, 16, and 96 h).

when compared with wild-type mice (P = 0.013; Fig. 5 B).
Moreover, although almost 30% of the MIF-KO mice survived to postinfection day 30, only 9% of wild-type mice
survived this long (P < 0.04).
To better assess the role of the host inflammatory response
in the development of anemia and lethality from P. chabaudi
infection, we measured the production of MIF and the cytokines TNFα and IFNγ, which serve as useful indicators of
systemic macrophage and T cell activation, respectively.
Plasma MIF concentrations reached 40 ± 20 ng/ml in wildtype mice at day 8 (Fig. 5 C). However, serum TNFα and
IFNγ levels showed no differences when measured in the
MIF-KO and wild-type strain during the period critical for
anemia and lethality. Collectively, these findings support an

important role for MIF, independent of the contribution of
TNFα or IFNγ, in the development of the malaria infection–related complications of anemia and death.
To further evaluate MIF’s role in the development of
anemia and erythroid suppression in this model of malaria infection, we next examined hematopoietic parameters in these
mice. Malaria infection produced a reticulocytosis in both
the wild-type and MIF-KO strains, but the corrected reticulocyte count was much greater in the setting of MIF deficiency (MIF+/+, 8 ± 5% vs. MIF−/−, 23 ± 10%; day 10 after
infection; P < 0.01). We also measured CFU-E and BFU-E in
bone marrow, and colony formation was significantly greater in
the P. chabaudi–infected MIF-KO mice than in the corresponding P. chabaudi–infected wild-type mice (P < 0.01; Fig. 6 A).

JEM VOL. 203, May 15, 2006
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Figure 5. Malaria-infected MIF-KO mice (MIF−/−) suffer from less
severe anemia and show increased survival when compared with
genetically matched wild-type controls (MIF+/+). (A) Time course for
the development of anemia as assessed by peripheral blood sampling
every other day. The data shown are the means ± SD (error bars) of 10
mice per group from one of two experiments that yielded similar results.
For differences in mean hemoglobin concentrations between the MIF+/+
and MIF−/− mice, P values are as follows: *, P < 0.01 for days 6, 8, and 15;
*, P < 0.05 for days 10 and 12. Because of low numbers of survivors, the
wild-type mice were not further studied after day 15. (B) Kaplan-Meyer

survival curves for MIF+/+ and MIF−/− mice after infection with
P. chabaudi AS. The data shown are for all mice studied (MIF+/+, n = 30;
MIF−/−, n = 31). The median survival was 13 d for MIF+/+ mice and 15 d
for MIF−/− mice. P = 0.0113 (two-tailed Mann-Whitney test); for overall
survival, P < 0.04 (χ2 test). (C) Plasma MIF, TNFα, and IFNγ concentrations measured by ELISA in P. chabaudi–infected wild-type (MIF+/+) and
MIF-KO (MIF−/−) mice. Cytokines were measured in triplicate. (The MIF-KO
mice do not produce any immunoreactive MIF product). For TNFα and
IFNγ, there were statistically significant increases on postinfection days 8
and 12 compared with uninfected controls in both strains (*, P < 0.001).

Notably, the levels of bone marrow production of the cytokines TNFα and IFNγ were indistinguishable in the infected
MIF-KO and wild-type strains, and the measured values
closely mirrored the circulating levels of these mediators
(Figs. 5 C and 6 B). The wild-type mice nevertheless showed
a prominent induction of MIF protein in the bone marrow
that increased over time during the period critical for anemia
development. These data collectively support the role of MIF
in erythroid suppression and that MIF deficiency is associated
with better compensation of erythropoiesis during experimental malarial infection.

Plasmodium falciparum–endemic region of Zambia. MIF was
measured in 20 children who were presented sequentially for
clinical evaluation and diagnosed with malaria by peripheral
blood smear. As shown in Fig. 7, there was a significant increase in the plasma concentration of MIF in malaria-infected
patients when compared with uninfected controls obtained
from the same geographic region. The median plasma concentrations of MIF in the malarial patients was 11.8 ng/ml
(0.9–49.5 ng/ml), which is comparable with the level reported previously in patients with bacterial sepsis (median of
12.2 ng/ml; reference 36). These data support the conclusion
that Plasmodium infection is a potent stimulus for the systemic
expression of MIF in human subjects.

MIF circulates in high concentrations in malaria patients
Recent investigations in human malaria have provided evidence for MIF production in the intervillous blood of pregnant women with placental infection (46, 47). To determine
whether clinical malaria infection is associated with an increase in MIF in the systemic circulation, we used a specific
sandwich ELISA to quantify MIF in patients residing in a
1190

A functional promoter polymorphism in human
MIF influences the MIF response to the malarial
product hemozoin
The evidence that MIF plays a role in malarial anemia
prompted us to examine whether genetic polymorphisms in
MIF IN THE PATHOGENESIS OF MALARIA ANEMIA | McDevitt et al.
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Figure 7. Plasma MIF concentrations are elevated in malariainfected individuals. MIF was quantified by sandwich ELISA in 20
sequentially diagnosed subjects with malaria presented to the Macha
Mission Hospital in Zambia. Control plasmas (n = 20) were obtained contemporaneously from uninfected hospital controls. The bottom, middle,
and top lines of the box mark the 25th, 50th, and 75th percentiles, respectively. The vertical line shows the range of values comprised between
the 5th and 95th percentiles. The mean plasma MIF concentrations for
the control and malaria groups were 5.4 and 13.6 ng/ml, respectively
(P < 0.005 by a two-tailed Student’s t test). Error bars represent SD.

Figure 6. Malaria-infected MIF-KO mice show enhanced bone
marrow erythroid progenitor maturation. (A) CFU-E and BFU-E
formation in cultured bone marrow cells harvested from P. chabaudi–
infected or uninfected mice on postinfection day 13. Colonies were
scored as described in Materials and methods, and the data shown are
the mean ± SD (error bars) of three mice per group. *, P < 0.01 for
MIF−/− versus MIF+/+. (B) TNFα, IFNγ, and MIF production in bone
marrow lysates obtained from P. chabaudi–infected wild-type (MIF+/+)
and MIF-KO (MIF−/−) mice. TNFα and IFNγ were measured by ELISA, and
the data shown are the mean ± SD for five mice per group. The timedependent increase in bone marrow MIF content was assessed by Western blotting of bone marrow samples (240 ng of total protein per lane)
as described in Materials and methods. The blots show the bone marrow
analysis of three mice that were studied (I, II, and III). The standard lane
(first) shows the immunoblotting intensity of 90 ng of recombinant
mouse MIF protein.

the human MIF gene influence the human host response to
malaria infection. Functional promoter polymorphisms in human MIF have been linked recently both to the incidence or
the severity of several inflammatory diseases in different populations (48–51). These genetic polymorphisms include a tetranucleotide sequence (CATT) that is repeated between five
and eight times in the MIF promoter (position −794). An increase in CATT repeat number produces a corresponding
JEM VOL. 203, May 15, 2006

increase in MIF promoter activity (48). Individuals with the
5-CATT (low repeat) MIF allele may be considered low MIF
expressors, and those bearing non–5-CATT repeats (6-CATT,
7-CATT, or 8-CATT) may be high MIF expressors.
Plasmodium-infected red cells stimulate MIF secretion by
cultured macrophages (30). To study the MIF response of
human cells, we elected to use hemozoin as a stimulant.
Hemozoin is a metabolite of Plasmodium hemoglobin degradation that accumulates within the reticuloendothelial system
of the infected host (52). Hemozoin induces cytokine release
from monocytes/macrophages (53, 54), and it constitutes a
Plasmodium-specific, pathogen-associated molecular pattern
for innate immunity by interaction with the innate receptor
TLR9 (55). We confirmed that hemozoin, which was prepared synthetically from heme chloride (53) and, thus, was
free of other Plasmodium-produced components, induces MIF
release from macrophages in a standardized culture system
(Fig. 8 A). We then added hemozoin to human monocyte
cultures of predetermined MIF genotype and found that cells
bearing the low expression 5-CATT (homozygous) allele
secreted lower levels of MIF than cells encoding the high
expression 6-CATT (homozygous) or 6-CATT/7-CATT
(heterozygous) alleles (Fig. 8 B). These experimental data,
which were obtained in vitro, suggest that the host MIF
genotype may influence MIF production in response to the
malarial product hemozoin.
DISCUSSION
Clinical observations have led to the concept that the nature of the host response critically influences the pathologic
manifestations of malaria infection. Young children and the
immunologically naive suffer disproportionately from lethal
malaria, and it is hypothesized that death results from an
exaggerated immunologic response such that the mechanisms
1191

Figure 8. Hemozoin-induced MIF release from mononuclear cells
is regulated by low and high expression MIF alleles. (A) Hemozoin
induces MIF release by cultured mouse macrophages. 2 × 106/ml thioglycollate-elicited peritoneal macrophages were cultured with synthetically
prepared hemozoin for the indicated times, and the conditioned medium
was harvested for MIF ELISA. Values shown are the mean of triplicate
determinations. (B) Hemozoin-stimulated human mononuclear cells encoding the high expression MIF alleles 6-CATT/6-CATT (6/6) or 6-CATT/7CATT (6/7) release more MIF protein than cells encoding the low
expression MIF allele 5-CATT/5-CATT (5/5). Cells were stimulated with
42 nM hemozoin for 48 h before sampling supernatants for MIF content.
Values shown are mean ± SD (error bars) of duplicate analyses. *, P <
0.002 for 6/6 versus 5/5; *, P < 0.001 for 6/7 versus 5/5; *, P < 0.02 for
6/7 versus 6/6.

initially recruited to fight infection become dysregulated and
produce life-threatening tissue damage (56, 57). Investigators
proposed many years ago that the specific pathogenic manifestations of malaria, such as severe anemia and cerebral malaria, result from proinflammatory mediator release by host
cells interacting with malaria parasites or their products (22).
Others reported evidence of a role for activated leukocytes in
the erythropoietic changes observed during malaria (18), and
some studies (19, 27) identified a host-derived circulating
mediator that acts to suppress erythropoiesis. Individual cytokines such as TNFα, IL-1, and IFNγ have been examined for
their effects on hematopoiesis, but their effects have been
judged to be minor or indirect; for instance, by inducing
other mediators or by affecting the distribution and availability of heme iron (20, 28, 58).
MIF has emerged to be an important regulator of innate
immunity (59). Its proximate actions are to promote downstream cytokine and Toll-like receptor expression (32, 60, 61)
1192

and to sustain cellular responses in the face of activationinduced apoptosis (62). MIF release from macrophages in
response to Plasmodium-infected red cells and its prominent
expression in the plasma, spleen, and bone marrow during
experimental malaria have suggested that MIF may mediate
erythropoietic suppression (30). Indeed, MIF shares each of
the properties that have been reported for the malariainduced erythropoiesis inhibitor. MIF levels closely correlate
with peak parasitemia, and its tissue and bone marrow production mimic the expression pattern of the malaria-induced
erythropoiesis inhibitor (19, 20, 28). MIF’s biophysical properties also match those that have been reported for the circulating inhibitor (31).
Hematopoietic colony assays confirm that MIF, in concentrations that circulate in patients with malaria infection, is
a direct and potent inhibitor of erythroid progenitor development. Our finding of synergistic inhibition by MIF together with low, subinhibitory combinations of TNFα or
IFNγ is not without precedent because similar synergism has
been observed in studies of MIF’s impact on proinflammatory monocyte/macrophage activation (31, 32). In the progenitor cell systems that were examined, MIF’s action was to
inhibit cytodifferentiation and hemoglobin production.
These data add to our understanding of the inflammatory
pathogenesis of malarial anemia, but it should be emphasized
that they do not exclude a role for yet additional mediators in
influencing erythroid development. Differential TH1 and
TH2 immunologic responses may influence the pathologic
course of malaria infection, and IL-10 and IL-12 deficiencies
also may contribute to anemia (15, 24, 26, 63). Whether
these effects can be attributed to the direct action of these
cytokines on erythroid progenitors or to regulatory effects
on other mediators, including MIF, remains to be examined.
There also is evidence from other disease models that proinflammatory cytokines may inhibit erythropoiesis by repressing the synthesis of erythropoietin (64). Clinical studies of
malarial anemia, however, suggest that erythropoietin levels
are appropriately elevated for the degree of anemia (14–16),
although this finding is not uniform (65, 66). High circulating erythropoietin levels point to an acquired resistance by
progenitor cells to erythropoietin stimulation, and this effect
has been recently verified in a study of P. chabaudi–infected
mice (21). Signal transduction through MAP kinases has been
implicated in the functional effects of erythropoietin (35, 40),
and our data indicate that signals delivered by MIF antagonize the normal pattern of MAP kinase phosphorylation that
is associated with the erythroid differentiation in a progenitor
line. The potential involvement of other signaling pathways
that are relevant for erythroid differentiation remain to be
examined, but an MIF-induced dysregulation in signaling
may contribute to the suppression of erythropoiesis that accompanies other inflammatory disease states as well (58).
The idea that MIF has an intrinsic role in the development of malarial anemia was verified by examining mice genetically deficient in MIF. MIF-KO mice infected with
P. chabaudi showed less anemia and decreased mortality when
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compared with their wild-type infected counterparts. Although it may be argued that the impact of MIF deficiency
on either mortality or anemia in this experimental mouse
model is not dramatic, it is consistent with MIF’s influence
on the component of anemia that is attributable to erythroid
suppression. Indeed, enumeration of bone marrow cultures
revealed increases in CFU-E and BFU-E of the malariainfected MIF-KO mice when compared with the wild-type
controls (P < 0.01).
Longitudinal studies in malaria patients to examine the
relationship between MIF production and hematologic indices will be important to perform. The levels of plasma MIF
that we detected in children with malaria are similar to those
reported previously in patients with bacterial sepsis, although
patients with septic shock show even higher circulating MIF
levels (36). Several case control studies have linked high
expression human MIF alleles (6-CATT, 7-CATT, and
8-CATT) or an associated single-nucleotide polymorphism
with different inflammatory diseases (48–51). It is noteworthy that there is considerable population stratification in the
distribution of MIF alleles, suggesting that this locus may
have been subject to differential selective pressure in different
regions or ethnic groups (67). We found that malarial hemozoin stimulates MIF protein production from primary human
mononuclear cells in amounts that reflect the low (5-CATT)
versus the higher (6-CATT and 7-CATT) expression genotype of the cells. Our data indicate that the MIF locus may
regulate the monocyte/macrophage response to this proinflammatory malarial product. Hemozoin is poorly degraded
in vivo, and, once formed in host tissues, it may act as a persistent inflammatory focus to sustain the production of MIF
and other cytokines. Hemozoin deposition within the bone
marrow (30) also may explain why reticulocytosis and bone
marrow recovery are often delayed despite the cure of infection in human malaria (8, 10). Our studies point to the deleterious effect of MIF on the clinical expression of malarial
anemia; however, it is important to consider that in the appropriate context, MIF also may exert important functions
in the immunologic response to Plasmodium infection.
Whether the human MIF gene influences the clinical expression of malaria and the development of complications
such as severe anemia is of interest, and this question can be
addressed by examining the association between MIF alleles
and disease manifestations in a malaria-endemic population.
Such information may facilitate the identification of individuals who are at high risk for severe malarial anemia or other
complications so that steps can be taken to prevent or better
treat their disease.
MATERIALS AND METHODS
Cytokines, antibodies, and reagents. Recombinant mouse or human
MIF were prepared, and the proteins were purified essentially free of endotoxin (<1 pg endotoxin/μg protein) as described previously (31). The neutralizing anti-MIF mAb (IgG1 isotype) and an isotypic control antibody
(5D4-11; American Type Culture Collection) were purified by Mono-Q
fast protein liquid chromatography. 2.7 × 105 U/μg recombinant mouse
TNFα and 8.4 × 103 U/μg IFNγ were obtained from R&D Systems.
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Hemozoin was prepared synthetically from hemin chloride (Sigma-Aldrich)
under endotoxin-free conditions (53).
Cytokine quantification. MIF was measured by sandwich ELISA (36) using human or mouse MIF-specific antibodies developed in our laboratory.
The MIF content of bone marrow was determined by Western blotting and
detection with rabbit polyclonal antibody. TNFα and IFNγ levels in sera
and in supernatants of bone marrow lysates were measured by the Quantikine M TNFα or IFNγ Immunoassay kit (R&D Systems).
Mice and mouse cell cultures. The MIF−/− (MIF-KO) mice (45) were
bred onto the BALB/c genetic background and studied between 8–10 wk of
age. The mice were at generation N6. All mouse studies were performed in
accordance with protocols approved by our Institutional Animal Care and
Use Committees.
Bone marrow precursors were harvested from the femora and tibia of
mice in 3 ml of Iscove’s modified Dulbecco’s medium containing 2% FBS.
The viability of marrow cells was determined to be >97% by trypan blue
exclusion staining. Bone marrow lysates were collected by flushing two
femurs and two tibias per mouse with 1 ml of lysis buffer (150 mM NaCl,
50 mM Tris, pH 7.5, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, and
2 mM EDTA) using a 25 G 5/8-gauge needle. The bone marrow plug was
homogenized, the cellular debris was pelleted, and the lysate supernatant was
concentrated using a Centricon 10 membrane (Amico). Mouse macrophages
were prepared from the adherent cultures of thioglycollate-elicited peritoneal macrophages as described previously (60).
BFU-E and CFU-E progenitor cell assays. The progenitor cell (colony)
assays were performed according to the standardized methods described previously (30) and protocols from StemCell Technologies Inc. In brief, washed
mouse bone marrow cells were plated in sterile 35-mm dishes containing a
methylcellulose-based medium and growth factors. The total number of
bone marrow cells plated in duplicate culture dishes were 2 × 105 for CFUE and 5 × 105 for BFU-E. MethoCult M3334 was used for the CFU-E and
BFU-E colony assays. The media for CFU-E and BFU-E was volume adjusted by adding one part Isocove’s modified Dulbecco’s medium to nine
parts MethoCult M3334 to give final concentrations of the following components: 15% FBS, 1% BSA, 200 mg/ml transferrin, 10 mg/ml insulin,
1% methylcellulose, 10−4 M 2-mercaptoethanol, 2 mM l-glutamine, and
3 units/ml erythropoietin. Each assay of different bone marrow progenitor
cells was performed independently three to six times.
Erythroid progenitor cell lines. The Friend MEL cell line was cultured
in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS.
Differentiation was induced with dimethyl sulfoxide differentiation medium
for 4 d as described previously (34). Hemoglobin synthesis was assessed by
cytocentrifugation onto glass slides followed by staining with benzidine
(Worthington) and a hemoglobin kit (Sigma-Aldrich).
The human K562 progenitor cell line (CCL-243; American Type Culture Collection) was cultured in RPMI/10% FBS supplemented with penicillin and streptomycin. For differentiation, sodium butyrate (Sigma-Aldrich)
was added to the medium (35). Terminal erythropoietic differentiation was
measured as described previously (38), and positive cells were enumerated
after staining with DAF (Sigma-Aldrich). To quantify hemoglobin synthesis,
the cells were centrifuged and washed in PBS, and the cell pellet was resuspended in lysis buffer (100 mM potassium phosphate, pH 7.8, and 0.2%
Triton X-100) before disruption by aspiration through a 21-gauge needle.
After microcentrifugation, the supernatant was collected, and the hemoglobin concentration was determined using a hemoglobin kit (Sigma-Aldrich).
Cell viability was assessed by trypan blue dye exclusion and found to be
equivalent (85–90% viability) between all samples studied.
Western blot analysis. Immunoblotting with antibodies directed against
phospho–ERK-1/2, total ERK-1/2, phospho–JNK-1/2, total JNK-1/2,
phospho-p38, and total p38 was performed according to the manufacturer’s
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instructions (New England Biolabs, Inc.). The secondary antibody was an
anti–rabbit IgG conjugated to horseradish peroxidase, and detection was by
chemiluminescence according to the manufacturer’s instructions (GE
Healthcare). For quantitation of signal intensity of phospho-specific kinase
results, Western blots were scanned using a scanner (PowerLook IIII;
UMAX), and the images were analyzed using UN-SCAN-IT gel Automated Digitizing system software version 5.1 (Silk Scientific). The ratio between phosphorylated and total MAP kinase was determined and expressed
as a fold change for each lane (mean ± SEM for three blots from independent cell cultures). The P values were calculated for each of the time course
comparisons (4, 16, and 96 h) of three different experiments (two-tailed
Student’s t test).
Mouse malaria studies. To maintain uniformity of infections, P. chabaudi
AS was maintained by serial passage in A/J mice, and no more than 10 passages were allowed before a fresh inoculum was prepared from frozen stocks.
For simple passages, infection was initiated with a dose of 106–107 parasitized
erythrocytes. For clinical infections, mice were inoculated intraperitoneally
with 106 parasitized red blood cells. The course of experimental infection in
mice was monitored every other day by examining DiffQuik (Baxter Scientific Products)-stained thin smears from blood. Parasitemias were determined
by counting a minimum of 200 erythrocytes per blood sample. Hemoglobin
was determined by using Drabkin’s procedure (Sigma-Aldrich) on 1 μl of
tail vein blood prepared on every second day, after infection, for 3 wk. Mice
were observed daily for at least 30 d, and mortality was recorded. At predetermined times after infection, five animals per group were killed by CO2,
and the blood was collected by cardiac puncture.
Human specimens and cell culture. Blood samples from 20 malaria patients and 20 uninfected, healthy controls were obtained from the Macha
Mission Hospital in Choma, Zambia, where P. falciparum is endemic. The
blood samples were obtained in accordance with research protocols approved by the institutional review boards of the University of Zambia and
Yale University. The subjects had acute onset malaria and were diagnosed
for clinical symptoms (fever, splenomegaly, headache, and malaise) and a
positive, thick blood film for parasites. The subjects (12 male and 8 female)
were between 5–52 mo of age (mean = 25.5 mo) and had a mean hemoglobin of 5.9 g/deciliter. Co-infection by organisms likely to contribute to a
systemic inflammatory response was excluded by clinical evaluation and laboratory testing. Numerical values obtained by MIF-specific sandwich ELISA
were confirmed semiquantitatively by Western blotting.
Human mononuclear cells were prepared from the adherent leukocyte
fraction of volunteers and genotyped for the (−794) CATT tetranucleotide
repeat and for a (−173) G/C single-nucleotide polymorphism (48). Two
homozygous and one heterozygous MIF promoter genotypes were studied:
5-CATT/5-CATT, 6-CATT/6-CATT, and 6-CATT/7-CATTC. The
mononuclear cells were cultured in 24-well plates (104 cells/well) and stimulated with 42 nM hemozoin for 48 h. Cells from three individuals were
studied within each genotyped group, and the results were repeated twice.
Statistics. Data are presented as means ± SD. The significance level for all
statistical tests was set at α = 0.05. One-way analysis of variance was performed to determine whether there were differences in the effects of MIF,
anti-MIF, TNFα, and IFNγ at various doses with respect to colony formation of bone marrow progenitor cells. Upon finding differences, Bonferroniadjusted pairwise (post-hoc) comparisons were performed to determine
which mediator–dose combination differed from one another. Comparisons
between cytokine levels, colony formation, and cytokine production between the MIF+/+ and MIF−/− mice and between normal and malariainfected mice were performed using the two-tailed Student’s t test. For mouse
survival, the median survival time was compared by the Mann-Whitney test,
and the overall survival was compared using the χ2 tests (68).
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